A large U.S. study found no evidence that taking Ozempic or Wegovy is tied to an increase in suicidal thoughts, researchers reported recently.

研究人员最近报告称，美国的一项大型研究发现，没有证据表明服用 Ozempic 或 Wegovy 与自杀念头增加有关。

Both Ozempic for type 2 diabetes and the obesity treatment Wegovy have the same active ingredient, semaglutide.

用于治疗 2 型糖尿病的 Ozempic 和治疗肥胖症的 Wegovy 都具有相同的活性成分：索马鲁肽。

The analysis included electronic medical record data from more than 1.8 million patients. Researchers actually found a lower risk of new and recurring suicidal thoughts in those taking semaglutide compared to those using other medications for weight loss or diabetes.

该分析包括超过 180 万名患者的电子病历数据。 研究人员实际上发现，与使用其他减肥或糖尿病药物的患者相比，服用索马鲁肽的患者出现新的和反复自杀想法的风险较低。

Semaglutide belongs to a class of drugs known as GLP-1 agonists, which were designed to treat type 2 diabetes. In addition to helping control blood sugar levels, the drugs produce a feeling of fullness.

索马鲁肽属于一类被称为 GLP-1 激动剂的药物，旨在治疗 2 型糖尿病。 除了帮助控制血糖水平外，这些药物还能产生饱腹感。

Concerns over reports of suicidal ideation connected with semaglutide led to an investigation by the European Medicines Agency. The U.S. Food and Drug Administration (FDA) has listed suicidal ideation as a possible safety concern for GLP-1 drugs.

由于对与索马鲁肽有关的自杀意念报道的担忧，欧洲药品管理局展开了调查。 美国食品和药物管理局 (FDA) 已将自杀意念列为 GLP-1 药物可能存在的安全问题。

A Reuters examination last year found that the FDA had received 265 reports of suicidal thoughts or behavior in patients taking semaglutide or similar medicines since 2010. Thirty-six of those reports describe a death by suicide or suspected suicide.

路透社去年的一项调查发现，自 2010 年以来，FDA 已收到 265 份关于服用索马鲁肽或类似药物的患者出现自杀想法或行为的报告。其中 36 份报告描述了自杀或疑似自杀死亡的情况。

Such events do not prove a connection between a drug and a side effect. But they can signal to officials a need to study a specific risk.

此类事件并不能证明药物与副作用之间存在联系。 但他们可以向官员发出信号，要求他们研究特定的风险。

The study appeared online in the journal Nature. It was funded by the U.S. National Institutes of Health. The researchers examined data on 240,258 U.S. patients prescribed Wegovy or other medications for weight loss and nearly 1.6 million with type 2 diabetes prescribed Ozempic or other treatments.

该研究在线发表在《自然》杂志上。 它由美国国立卫生研究院资助。 研究人员检查了 240,258 名美国患者服用 Wegovy 或其他减肥药物以及近 160 万 2 型糖尿病患者服用 Ozempic 或其他治疗药物的数据。

Researchers compared nearly 53,000 Wegovy patients to the same number of closely matched users of other weight-loss drugs.

研究人员将近 53,000 名 Wegovy 患者与同等数量的其他减肥药使用者进行了比较。

They found that during the first six months of use, first-time suicidal thoughts were reported by 0.11 percent of Wegovy users. That is compared to 0.43 percent of users of other drugs that do not belong to the same class as semaglutide.

他们发现，在使用 Wegovy 的前六个月内，0.11% 的 Wegovy 用户报告了首次自杀念头。 相比之下，使用与索马鲁肽不属于同一类别的其他药物的比例为 0.43%。

After taking other risk factors into consideration, the risk of first-time suicidal thoughts was 73 percent lower with Wegovy, the researchers said.

研究人员表示，在考虑其他风险因素后，使用 Wegovy 后首次自杀念头的风险降低了 73%。

No patient in the Wegovy group reported a suicide attempt, compared to 14 users of the other drugs, the report said.

报告称，与其他药物的 14 名使用者相比，Wegovy 组中没有患者报告有自杀企图。

Among patients with a history of suicidal thoughts, the risk of recurring suicidal thoughts was 56 percent lower with Wegovy than other weight-loss medicines.

在有自杀念头史的患者中，使用 Wegovy 后再次出现自杀念头的风险比其他减肥药物低 56%。

Similar patterns were seen for use of Ozempic compared with other diabetes drugs.

与其他糖尿病药物相比，Ozempic 的使用也出现了类似的情况。

The findings were consistent no matter the patients’ sex, age, or ethnicity for both semaglutide types, the researchers found.

研究人员发现，无论患者的性别、年龄或种族如何，两种索马鲁肽类型的研究结果都是一致的。

Such a study cannot prove that GLP-1 agonists do not increase the risk of suicidal ideation. But the findings may reduce concerns.

此类研究无法证明 GLP-1 激动剂不会增加自杀意念的风险。 但研究结果可能会减少担忧。

The researchers were unable to assess the statistical significance of differences in actual suicide attempts. The researchers noted that suicide attempts are "critically different from suicidal ideations."

研究人员无法评估实际自杀企图差异的统计显着性。 研究人员指出，自杀企图“与自杀意念截然不同”。

Pamela Davis is a professor at Case Western Reserve School of Medicine in Ohio. She was one of the writers of the study. She said the growth in popularity of Ozempic makes it very important “to understand all its potential complications.”

帕梅拉·戴维斯是俄亥俄州凯斯西储医学院的教授。 她是该研究的作者之一。 她说，Ozempic 越来越受欢迎，因此“了解其所有潜在并发症”变得非常重要。

Suggestions that the drug may cause suicidal thoughts are not supported by “this very large and diverse population in the U.S.,” Davis added.

戴维斯补充说，“美国人口众多且多样化”并不支持这种药物可能导致自杀念头的说法。